Share on

Global Immunotherapy Drugs Market Size, Share, Trends, COVID-19 Impact & Growth Analysis Report – Segmented By Drug Type, Application & Region - Industry Forecast (2022 to 2027)

Published: January, 2022
ID: 1092
Pages: 175
Formats: report pdf report excel report power bi report ppt

Immunotherapy Drugs Market Size (2022 to 2027)

The size of the global immunotherapy drugs market was worth USD 92.29 billion in 2022. This value is further forecasted to grow USD 152.04 billion by 2027, growing at a CAGR of 10.5% between 2022 to 2027.

Immunotherapy is a biological therapy used to treat cancer patients. Immunotherapy is a treatment given to restore or stimulate the ability of the defense system (immune system) to fight infection and disease. It is also called biological therapy and is a form of treatment using the body's natural ability that constitutes the immune system to fight against disease and protects the body from other side effects. Immunotherapy always has a vital role in the process of treatment of vulnerable diseases.


The global immunotherapy drugs market is driven by factors like the quick approval process of drugs, an increase in the adoption of targeted therapies, and a high rise in lifestyle diseases.

The growing prevalence of Cancer and the accelerating aging population worldwide is majorly increasing the demand for immunotherapy drugs. According to the WHO, in 2016, nearly 1.75 million cancer patients are discovered in the U.S. only. According to the CDC, almost 1.5 million people are examined with cancer every year in the U.S. More than lakhs of people are striving hard to survive due to cancer. One of the main factors that lead to lung cancer is smoking and consumption of alcohol, where 90% of men and 80% of women are suffering. Reports say that out of 6 patients, one patient die due to this cancer. The immunity system comprises WBC, which helps the body fight against diseases and makes the body stay healthy. Different types of immunotherapies are used for the treatment of cancer disease.

The U.S FDA has accepted 32 new drugs for different immunotherapies for patients fighting cancer like melanoma, breast cancer, lung cancer, kidney cancer, breast cancer, etc. Immune-modulators, cell-based immunotherapies, and vaccines are some of the treatments for cancer therapy.

An increase in options in the existing markets and immunotherapy is another possibility to chemotherapy for the first-line treatment is the factors that support the growth of the global immunotherapy drugs market and the key players in the coming future. Next-generation treatment options offer the opportunity for new upcoming and improved techniques of anti-cancer therapy. Critical areas of possibility in this market include developing countries and the growing adoption of immunotherapy.


With the high cost of the treatment of immunotherapy and high reduction of strength and effectiveness, the rate of the product development cycle is hindering the global immunotherapy drugs market growth.

Lack of knowing immunotherapy drugs and also overall costly treatment is restraining the market. Side effects of immunotherapy on another body are supposed to limit the growth of the global immunotherapy drugs market.

The challenge of immunotherapy is to improve the effectiveness and patient responsive rates. Additional makers would help find a way to challenges posed by tumor heterogeneity because of the probability of targeting more than one cell type to recognize multiple types of antigens. The high cost of the products is one of the significant challenges to the Global Immunotherapy Drugs Market.

COVID-19 impact on the global immunotherapy drugs market:

COVID 19, which is termed after the novel virus corona, has the most significant demand for immune therapy drugs. As seen from the last few months, immunocompromised persons are affected more by this virus. Immunotherapy drugs help to fight external foreign factors attacking the body. Immunotherapy drugs cover types of monoclonal antibodies, adult vaccines, checkpoint inhibitors, and Alpha and beta interleukins.




Market Size Available

2021 to 2027

Base Year


Forecast Period

2022 to 2027

Segments Analysed

By Drug Type, Application, and Region

Various Analyses Covered

Global, Regional & Country Level Analysis, Segment-Level Analysis, Drivers, Restraints, Opportunities, Challenges, PESTLE Analysis, Porter’s Five Forces Analysis, Competitive Landscape, Analyst Overview on Investment Opportunities

Regions Analysed

North America, Europe, Asia Pacific, Latin America, Middle East, and Africa


This research report on the global immunotherapy drugs market has been segmented and sub-segmented based on the drug type, application, and region.

Immunotherapy Drugs Market - By Drug Type:

Based on drug type, Monoclonal antibodies are among the most in-demand models of immunotherapy drugs that are likely to register the highest growth rate in the coming years. The Monoclonal Antibodies segment is expected to have the most massive share market value. It is attributed to growing regular approvals and a higher ability to produce the desired result. This segment has the largest share due to the growing amount of funds used for research and development and for treating cancer patients. This segment has a CAGR value of 7.25% during the period.

Immunotherapy Drugs Market - By Application:

  • Blood Cancer
  • Cervical Cancer
  • Breast Cancer
  • Glioblastoma
  • Lung Cancer
  • Gastric Cancer
  • Prostate Cancer
  • Melanoma

Based on the Application type, all kinds of Lung Cancer segments are accounted to hold the largest share in the market. The Application segment consists of the types of cancer in which lung cancer holds the highest share due to the increase of lung cancer patients. Patients support these cancer treatments as they have very few side effects that can accelerate the growth of the immunotherapy drugs market.

Immunotherapy Drugs Market - By Region:

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

The North American region is expected to have the largest share market and is likely to continue over the period. The largest share in this region is due to supportable reimbursement policies; increasing the combining of research institutes, and the companies are one reason for this region's growth.

The North American region follows Europe. It is likely to grow with is a short period during the period attributed due to the adoption of advanced cancer therapeutics for effective treatment.

The Asia-Pacific is likely to have faster growth in the upcoming years. Due to the rapid development of healthcare technology, large patient population and large amount spent on healthcare, high disposable income, increase in health and hygiene associated with awareness.

Latin America is likely to have an average amount of growth due to the existing pharmaceutical manufacturers in this region. The increase in this region is due to the growing existence of major pharmaceutical producers in the countries of this region.


Some of the notable companies leading the global immunotherapy drugs market profiled in this report are Merck, Roche, Eli Lilly, Amgen, Novartis, Celgene, AstraZeneca, Bristol Myers Squibb, GlaxoSmithKline PLC, and Seattle Genetics.


  • On January 07, 2019, Alligator Biosciences announced a novel concept in bispecific antibody formats RUBY. The ability to give generative therapeutic antibodies that are both efficient and highly manufacturable. 
  • On November 21, 2019, Myriad Genetics announced that Japan’s Health, Welfare, and Labor had approved the BRAS Analysis Diagnostic system to help physicians determine which women with breast cancer and have Hereditary Breast and Ovarian Cancer syndrome. 
  • On December 30, 2019, The US FDA approved AstraZeneca Lynparza and Myriad Genetics’ CDx for BRCA as a maintenance treatment for certain metastatic pancreatic cancer patients. 
  • On November 11, 2019, Myriad Genetics presents new test Data in the Autoimmune system at Annual Meeting in Atlanta, GA. 
  • On October 23, 2019, The U.S. FDA expanded the approval for GSK’s as a fourth-or later line treatment option for the advanced ovarian, fallopian tube, or primary peritoneal cancer patients who have homologous recombination deficiency. 

Please wait. . . . Your request is being processed

Related Reports

Access the study in MULTIPLE FORMATS
Purchase options starting from $ 2500

Didn’t find what you’re looking for?

Need something within your budget?


Call us on: +1 888 702 9696 (U.S Toll Free)

Write to us:

Click for Request Sample